Proactive Investors - Run By Investors For Investors

Supreme to raise another $1 mln for Kincardine medical marijuana facility

Supreme to raise another $1 mln for Kincardine medical marijuana facility

Supreme Pharmaceuticals (CSE:SL) says it will raise up to $1.0 million via a non-brokered private placement financing, with the funds to be used for the continued development of its Kincardine medical marijuana facility.

The company will issue up to 3.12 million units at a price of 32 cents apiece. Every unit will be made up of one common share, and one half of a share purchase warrant, with each whole warrant entitling the holder to buy an additional share for 50 cents, for a period of two years from closing.

The offering is expected to close November 17.

The news comes on the heels of Supreme raising a total of $2.6 million from a two-part financing earlier this month. The Vancouver, BC-based company will put all the money towards the development of its Kincardine medical marijuana facility, which is approaching the production phase. 

Due to strong support from the local community, Supreme has been able to move quickly to implement its proposed plan to produce up to 24 million grams of medical marijuana, for which it received conditional pre-approval from Health Canada in January.

To move to post-license production status, the company has to adopt the high-level security measures required by Health Canada at the 342,000 square foot operation. Health Canada also has to perform a final inspection of the facility. 

In September, Supreme said that it anticipates being ready for the pre-license inspection by Health Canada to verify its compliance with the requirements of the new MMPR (Marijuana for Medical Purposes Regulations) program in November.

Given the size of the facility, Supreme will bring on production gradually, tailoring output to meet the strain and volume demands of the market. 

Late last month, Supreme also appointed start-up maven Chris Bechtel to its advisory board as the company gets ready to usher in a new development phase. Bechtel launched a small oil and gas business in Houstun Texas in 1983 that was sold to in 2006 to Weatherford International, one of the largest global providers of oil and gas services. 

Bechtel also has experience in the medical marijuana industry, after investigating the medical benefits of cannabis for an immediate family member. He has since become a private investor in over a half a dozen companies in the cannabis sector, as well as become a consultant and advisor to these businesses. 

View full SL profile View Profile

Supreme Pharmaceuticals Timeline

Related Articles

skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Enzymes under a microscope
April 28 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use